Patent information
IP India · live recordAbstract
An expandable drug delivery system comprising of one or more actives, force generating components, optionally containing one or more absorption modifiers
Applicants
1Inventors
3Claims
10Specification
Show full textCollapse
FIELD OF INVENTION The invention relates to a drug delivery system of macromolecular active ingredients, one or more force generating components matrix, absorption modifiers The active ingredient is entrapped into the matrix of a mucoadhesive polymer matrix optionally coated with a degradable layer. The invention is also intended for the delivery of hydrophilic drugs in the intestinal tract. BACKGROUND OF THE INVENTION Therapeutics like protein, peptide and nucleotide are unstable against acidic, alkaline and/or enzymatic degradation upon systemic uptake and additionally they show poor intestinal absorption due to their high hydrophilicity. Therefore, these compounds are administered by parenteral injection, which has the disadvantages of painful application, risk of infections, low patient compliance and the need of trained personnel. Usually, oral route is the easiest and most preferred way of drug administration for most high molecular weight drugs or active ingredients. In general the oral absorption of peptide drugs like insulin is hampered by the properties of the drug since the peptide molecule is unable to cross the lipophilic enterocyte membrane and also due to the hostile environment of the gastro-intestinal tract (high acid concentration in the stomach and high amount of enzymes (peptidases)) in the lumen of the gut). Most of the published peptide delivery systems for oral application are micro- or nanosized systems based on mucoadhesive and multifunctional polymers which are able to adhere to the enteral mucosa for a certain period of time, interact with the tight junctions protein to reversibly open the tight-junctions, to locally de-activate the gut enzymes and to finally release the peptide drug. However it turned out that such micro- or nanosized delivery platforms are only in invivo studies able to induce substantial blood peptide drug levels in small animals like mice and rats, but unable to result in similar blood peptide levels in bigger animals like pigs of 25 - 30 kg or humans.
The reason for this most probably is the overall presence of soluble mucins in the lumen of the gut where the mucoadhesive drug delivery systems are released and their mucoadhesive properties (which are the essential feature for functioning of the delivery system) are immediately deactivated by the soluble mucins before the micro/nanosized delivery systems have reached the absorbing membrane of the enterocytes. Attempts employing mucoadhesive polymers have been rather successful in vitro and in vivo (example: H. L.Lueben et al; Pharm. Res.1995,12: 1293-1298; H. L.Lueben et al. ; Pharm. Res. 1996,13: 1668-1672). However, the turn-over of intestinal mucus covering the epithelium led to a rapid delocalization of the polymeric delivery system (C.-M. Lehr et al. ; Int. J.Pharm. 1991,70: 235-240). It would thus be desirable to have a system that is retained in the GIT such as at specific sites in the gut, e.g. by controlled swelling and bioadhesion over a predetermined and extended period of time. Such systems would have distinct advantages over other delivery systems in terms of therapeutic effect, patient compliance and manufacturing feasibility. WO-A-98/36739 discloses a multiphase release system for implantation purposes. More in particular, a non-compressed drug delivery system is described comprising one or more active ingredients in a solid matrix having a three dimensional architecture, which matrix comprises a bulk material in powder form and a binder. The disadvantage is that the delivery system has to be implanted by painfull surgical procedures. EP-A-0 873 750 discloses tablets for localized drug delivery of actives. These tablets adhere to biological material by means of a bioadhesive layer that becomes adhesive after impregnation with water or biological fluids. After adhesion, an active ingredient is released. The matrix system consists of polymers such as cellulose derivatives. The drug delivery system in presence of food will not have a desired release pattern.
US 5292518 discloses a prolonged release composition consisting of active, gel forming dietary fiber and mineral salts which release gas up on ingestion. The delivery system described above is not feasible for site-specific drug delivery (small intestine). EP0542364 discloses a device, which essentially contains an aperture through which the drug is released. The release rate is independent of the environmental pH and released drug even in stomach. This sort of a delivery system is a disadvantage for the acid sensitive active agents like peptides and proteins. Studies has been done to prepare a floating drug delivery systems of the orally active drugs where the investigators attempted to delivery the drug from a floating dosage form in the contents of the GIT released the drug in the stomach. The disadvantage is that it is not a suitable site for active agents like peptides or proteins. WO01/30322 has disclosed the use of super porous hydrogels (SPHs) or SPHs Composites (SPHCs) the latter system also containing a super disintegrant like Ac- Di Sol. which swells up on contact with aqueous fluid up to 200-fold of their dry volume and contains voids filled with drug composition which are sealed and coated mucoadhesive polymers, optionally enteric coated upon rupture of the enteric coating swells to mechanically fixed for a certain period of time at a desired position of the intestine, to bring the peptide delivery subunit system in direct contact with the mucosal membrane on the entrecotes and to release the drug. Afterwards the SPHs or SPHC carrier systems (shuttle system) is over hydrated and broken down by the peristaltic forces of the gut and excreted as fine polymer powder. The invivo study in pigs resulted in reproducible absolute bioavailabilities of 16± 3.3%. (F.A. Dorkoosh et.al; J. Control. Release. 2004,99:199-206) These SPHs and SPHCs formulations fulfill the requirements bringing the peptide drugs in direct contact with the absorption membrane. However the synthesis and
fabrication of the delivery systems is based on SPHs or SPHCs technology, which is difficult and not commercially feasible on production scale. Another disadvantage is their big size (i.e. capsule size 000), which is not easy to be swallowed. Hence the new invention aims at developing a modified formulation, which overcomes the demerits associated with the exiting technologies disclosed in the prior art. OBJECTIVES OF THE INVENTION The primary objective of the invention is to deliver primarily hydrophilic actives to the intestinal tract and to make their absorption across the intestinal wall possible by brining the active compounds in direct contact to the absorbing membrane of the gut tissue using mucoadhesive polymer. Another objective of the invention is to protect the active ingredients from the low pH of the gastric fluid and the digestive enzymes of the Gl lumen. Another objective of the invention is to prepare an expandable drug delivery system, which retains for a longer period of time at the specific site of absorption and delivers the drug at a predetermined rate through the mucus membrane. Another objective of the invention is to use a delivery platform for the drug carrier nanosized particles or capsules, microsized particles or capsules including liposomes or other similar systems, micro tablets or microcapsules, quantum dots or similar systems. Another objective of the invention to prepare an expandable drug delivery system by using the simple process with out involving complex procedures.
Another objective of the invention to prepare an expandable drug delivery system comprising absorption modifiers to facilitate opening of the tight junctions of the intestinal epithelium. Another objective of the invention to deliver the peptide drugs (which are sensitive to the pH and the digestive enzymes of GIT) with out exposing the drug to the GIT contents. Yet another objective of the invention is to release the drug at the specific site after a lag time, which is achieved by enteric coating. SUMMARY OF THE INVENTION The present invention relates to the preparation of a drug delivery system comprising of actives, swellable force generating component, absorption modifiers, optionally coated with enteric coating polymers. The preparation may further include pharmaceutical excipients or carriers. The present invention also relates to preparation an expandable drug delivery system, which delivers the drug at a specific site of the intestinal tract by adhering to the mucous membrane using bioadhesive polymers. The present invention also aims at the preparation of an expandable delivery system wherein the dosage form after administration reaches the desired site of action forms for a temporary adhesion to the mucous surface followed by imbibing the intestinal fluids into the core, where it dissolves the absorption modifiers in the core which generate a force to expand the dosage form and to adherers firmly to lumen. The drug present diffuses through the polymer matrix and is absorbed by the intestinal wall primarily by the paracellular pathway. The delivery system, which got adhered to the walls of the intestine, slides down as the mucous membrane shuds down and reaches the large intestine where the dosage from is degraded or expelled as such.
The dosage form of the present invention may contain carbon dioxide releasing agent which releases carbon dioxide, that forms a bubble layer around the dosage form which acts as a protective layer against enzymatic degradation. The bubble layer formed by gas generating component will remain intact in the dosage form until it reaches the intestinal wall and adheres to the intestinal mucosa. As the dosage form enters into the intestine the enteric coating dissolves and the bubble layer formed due to the gas releasing agent that will prevent the hydration of the mucoadhesive polymer which in turn prevents the dosage form to adhere to the mucin or mucosa till it reaches the specific site. DETAILED DESCRIPTION OF THE INVENTION An expandable drug delivery system is a system, which consists of more the one unit each unit acts a separate delivery system and consists of active agent in it. The expandable drug delivery system may be a multiparticulate or non-multiparticulate system. Multiparticulate is manufactured with any of the technique known in the prior art or known to the person skilled in the art. Some of the examples of multiparticulate drug delivery system but not limited to these examples nanoparticles or nanocapsules, micro particles or microcapsules, liposomes or niosomes in unilamellar or multilamellar structure, micro tablets or quantum dots, pellets or all other delivery systems which are filled in the capsules or punched in to mini tablets and filled in to capsule or compressed in to tablets. The non-multiparticulate drug delivery system is prepared by conventional granulation technique or by hot melt technique where in the non-multiparticulate is a monolithic tablet prepared by hot melt technique. The term "Absorption modifiers" is defined as the substances that influence absorption of a drug in the gastrointestinal tract by an increase in the rate and/or the extent of absorption of the drugs that are known or suspected of having poor
bioavailability. It is believed that such increase can rise from one or all of the following mechanisms: 1. reducing the thickness and/or the viscosity of the mucus layer which is present adjacent to the gastrointestinal mucosa. 2. alteration of the tight junctions between cells, thus promoting absorption through the paracellular route. 3. inducing a change in the cell membrane structure, thus promoting transcellular absorption. 4. increasing the hydrophobic environment within the cellular membrane. "Bioadhesion" is defined as the ability of a material to adhere to a biological tissue for an extended period of time. Bioadhesion is one solution to the problem of inadequate residence time resulting from stomach emptying and intestinal peristalsis, and from displacement by ciliary movement. For sufficient bioadhesion to occur, an intimate contact must exist between the bioadhesive and the receptor tissue, the bioadhesive must penetrate into the crevice of the tissue surface and/or mucus, and mechanical, electrostatic, or chemical bonds must form. Bioadhesive properties of polymers are affected by both the nature of the polymer and by the nature of the surrounding media. Bioadhesive and mucoadhesive can be used interchangeably. "Optional" or "optionally" means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not. The term "Carrier or excipients" comprised of a material that is not biologically or otherwise undesirable. The carriers or excipients may include any biologically inactive substance known in prior art used for the preparation of any pharmaceutical dosage form.
The formulation will, in general comprise of one or more excipients. Examples of excipients include, but are not limited to, diluents, disintegrants, lubricant, glident, binders, fillers, surfactant, solubilizers, and wetting agents. A combination of excipients may also be used. Such excipients will include diluents such as mannitol, dextrose, xylitol, sorbitol, gelatin, acacia, sucrose, microcrystalline cellulose, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulfate, lactose, starches, vinyl polymers and the likes, disintegrants referred to in the present invention include one or more of microcrystalline cellulose, croscarmellose sodium, crospovidone, carboxymethyl starch sodium, sodium starch glycolate and the likes, binders referred to in the present invention include one or more celluloses such as hydroxypropyl cellulose, hydroxy ethyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose or mixtures thereof, acrylates, methacrylates, povidone, sucrose, corn or maize starch, pregelatinized starch and the like, coloring agents such as ferric oxide, FD&C dyes, lakes and the likes and flavoring agent. Examples of glidents include but are not limited to silica, magnesium trisilicate, powdered cellulose, talc, and starch. The term "force-generating component" is defined as the component that is responsible for generating force for expanding the drug delivery system and give sufficient strength to transport the drug to the absorbing membrane for the time period sufficient to release the drug. The force generating component comprise of gas generating components like carbon dioxide or sulphur dioxide releasing agents e.g. acid base mixtures, carbonates, bicarbonate and sulfites, swelling polymers, osmogens and the like The term "expandable drug delivery composition" is a delivery system which can expand or swell, which is fabricated in combination of gas forming compounds, swellable polymers and mucoadhesive polymers that adhere to the mucous membrane and expand on hydration due to the force generating component and adheres to the side of the lumen.
The term "multilayered dosage form" is a dosage form which is made up of one or more layers. If it is more than on layer the layers can be laminated horizontally, vertically or by concentric layered (where in the core has a coated layer). The delivery system can release sub unit delivery platforms, which are driven either by the swellable polymers or by the gas to absorbing membrane. These sub-units delivery system can consist of nanoparticles or nanocapsules, micro particles or microcapsules, liposomes or niosomes in unilamellar or multilamellar structure, micro tablets or quantum dots or all other delivery systems sized from 4 mm down to nanometer size, with or with out mucodhesive properties using mucoadhesive polymers as described below with or with out substances which allow endocytosis or transcytosis of the particles across the enterocyctes of the intestine (like invasions and other similar particles across the enterocytes of the intestine (like invasions and other similar substances), with or with out enzyme inhibitors as described below Active agents suitable for use in the present invention include biologically active agents (actives) and chemically active agents, including, but not limited to, pharmacological agents, and therapeutic agents. Suitable active agents include those that are rendered less effective, ineffective or are destroyed in the gastro-intestinal tract by acid hydrolysis, enzymes and the like. Also included as suitable active agents are those macromolecular agents whose physiochemical characteristics, such as, size, structure or charge, prohibit or impede absorption when dosed orally. For example, biologically or chemically active agents suitable for use in the present invention include, but are not limited to, proteins; polypeptides; peptides; hormones; polysaccharides, and particularly mixtures of muco-polysaccharides; carbohydrates; lipids; other organic compounds; and particularly compounds which by themselves do not pass (or which pass only a fraction of the administered dose) through the intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastro-intestinal tract; or any combination thereof.
Further examples include, but are not limited to, the following, including synthetic, natural or recombinant sources thereof: growth hormones, including human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, and porcine growth hormones; growth hormone releasing hormones; growth hormone releasing factor, interferons, including [alpha] (e.g., interferon alfacon-1), [beta] and [gamma]; interleukin-1; interleukin-2; glucagon; insulin, including porcine, bovine, human, and human recombinant, optionally having counter ions including zinc, sodium, calcium and ammonium; insulin-like growth factor, including IGF-I; heparin, including un-fractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin and ultra low molecular weight heparin; calcitonin, including salmon, eel, porcine and human; erythropoietin; atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; protease inhibitors; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; luteinizing-hormone-releasing-hormone; follicle stimulating hormone; glucocerebrosidase; thrombopoietin; filgrastim; prostaglandins; cyclosporin; vasopressin; cromolyn sodium (sodium or disodium chromoglycate); vancomycin; desferrioxamine (DFO); bisphosphonates, including alendronate, tiludronate, etidronate, clodronate, pamidronate, olpadronate, and incadronate; parathyroid hormone (PTH), including its fragments; anti-migraine agents such as BIBN-4096BS and other calcitonin gene-related proteins antagonists; glucagon-like peptide 1 (GLP-I); antimicrobials, including antibiotics, anti-bacterials and anti-fungal agents; vitamins; analogs, fragments, mimetics or polyethylene glycol (PEG)-modified derivatives of these compounds; or any combination thereof and the like. Non-limiting examples of antibiotics include gram-positive acting, bacteriocidal, lipopeptidal and cyclic peptidal antibiotics, such as daptomycin, Aliskerin and analogs thereof. The present invention may comprise of active agent, a carrier and at least one swellable polymer.
A swellable polymer is a polymer that expands upon ingestion such that the pharmaceutical composition is retained in the stomach for 30 minutes, 90 minutes, 4 hours, 6 hours, 12 hours or 24 hours or more after administration. For example, the swellable polymer may cause the pharmaceutical composition to increase in size 10%, 15%, 50%, 100% or 200% or more as compared to its pre-ingested volume. Generally higher molecular weights of the polymers are more desirable since they provide a larger swollen size and stronger mechanic strength. In one embodiment of the present invention, the swellable polymers has a molecular weight in excess of 50,000 daltons. In another embodiment, the swellable polymer has a molecular weight in excess of 200,000 daltons. In another embodiment, the swellable polymer has a molecular weight in excess of 7,000,000 daltons. Swellable polymers include, but are not limited to, a crosslinked poly(acrylic acid), a poly (alkylene oxide), a polyvinyl alcohol, a polyvinyl pyrrolidone); a polyurethane hydrogel, a maleic anhydride polymer, such as a maleic anhydride copolymer, a cellulose polymer, a polysaccharide, starch, and starch based polymers. Examples of poly (alkylene oxides) include, but are not limited to, polymers, which contain as a unit, ethylene oxide, propylene oxide, ethylene oxide, or propylene oxide. These polymers may consist entirely of any of the above units (as a monomer), combinations of any of the above units, such as a copolymer. In one embodiment, the swellable polymer is a block copolymer in which one of the repeating units consists of ethylene oxide, propylene oxide, ethylene oxide, or propylene oxide. Examples of cellulose polymers include, but are not limited to, cellulose, hydroxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxy propyl methylcellulose (also known as hypromellose), and carboxymethyl cellulose.
Examples of polysaccharides include, but are not limited to, dextran, xanthan gum, gellan gum, welan gum, rhamsan gum, sodium alginate, calcium alginate, chitosan, gelatin, and maltodextrin. Examples of starch-based polymers include, but are not limited to, hydrolyzed starch polyacrylonitrile graft copolymers, starch-acrylate-acrylamide copolymers. Commercially available swellable polymers include Polyox 303(TM) (Polyethylene oxide), molecular weight 7,000,000); Polyox WSR N-12K (Polyethylene oxide), molecular weight 1,000,000), Polyox WSR N-60K (Polyethylene oxide), molecular weight 2,000,000), Polyox WSR 301 (Polyethylene oxide), molecular weight 4,000,000), Polyox WSR Coagulant, PolyoxWSR 303, Polyox WSR 308, NFgrade(TM) (Polyethylene oxide) molecular weight 1,000,000). Addition of hydro-attractants can improve the swelling properties of a dosage form significantly, and hence can constitute a swellable polymer. Examples of hydro-attractants which can be incorporated into pharmaceutical compositions of the present invention include crosslinked poly(acrylic acid), crosslinked poly(vinyl pyrrolidone), microcrystalline cellulose, crosslinked carboxymethyl cellulose, starch granules, sodium carboxymethyl starch, alginates, low substituted hydroxypropyl cellulose (L-HPC, 10-13% substitution by weight, Shin-Etsu Chemical Company, Ltd, distributed by Biddle Sawyer), Croscarmellose Sodium (Primellose) (Avebe, distributed by Generichem), Sodium Starch Glycolate (Avebe, distributed by Generichem) sodium phosphates, such as disodium phosphate, sodium chloride, sodium citrate, sodium acetate, succinic acid, fumaric acid, tartaric acid, tannic acid, sugars (eg. mannitol, sucrose, lactose, fructose, sorbital) and natural amino acids. Amino acids can also be used as permeation enhancers. Swellable polymers can also be used as rate controlling polymers. Release controlling polymers are often selected from the same class as swellable polymers. Examples of release controlling polymers include, for example, poly(ethylene oxide),
poly(acrylic acid), polyvinyl alcohol, alginate, chitosan, polyvinylpyrrolidone, cellulose polymers and polysaccharides and the like. An orally ingested product swells and adhere to either the epithelial surface or the mucus lining of the gastrointestinal tract. For the delivery of bioactive substances, it can be advantageous to have a polymeric drug delivery device adhere to the epithelium or to the mucous layer. Bioadhesion in the gastrointestinal tract proceeds in two stages: (1) viscoelastic deformation at the point of contact of the synthetic material into the mucus substrate, and (2) formation of bonds between the adhesive synthetic material and the mucus or the epithelial cells. In general, adhesion of polymers to tissues may be achieved by (i) physical or mechanical bonds, (ii) primary or covalent chemical bonds, and/or (iii) secondary chemical bonds (i.e., ionic). Physical or mechanical bonds can result from deposition and inclusion of the adhesive material in the crevices of the mucus or the folds of the mucosa. Secondary chemical bonds, contributing to bioadhesive properties, consist of depressive interactions (i.e., Van der Waals interactions) and stronger specific interactions, which include hydrogen bonds. The hydrophilic functional groups primarily responsible for forming hydrogen bonds are the hydroxyl and the carboxylic acid groups. Duchene et al, in Drug Dev. Ind. Pharm., 14:283-318 (1988), review the pharmaceutical and medical aspects of bioadhesive systems for drug delivery. Polycarbophils and acrylic acid polymers were noted as having the best adhesive properties. Others have explored the use of bioadhesive polymers, however, the extent of bioadhesion achieved in these studies has been limited. In addition, these studies do not demonstrate how to prepare larger bioadhesive drug delivery devices, such as tablets. WO 93/21906 discloses methods for fabricating bioadhesive microspheres and for measuring bioadhesive forces between microspheres and selected segments of the gastrointestinal tract in vitro.
Separately or in addition to the need to control the location at which a drug is released, there is also a need to control the duration over which a drug is released from a pharmaceutical formulation. In particular, certain drugs, especially peptide drugs are inactivated by enzymatic degradation if those released in the stomach. Thus, there is a need for methods for increasing the bioadhesion and thereby absorption of pharmaceutical agents from drug delivery systems such as tablets or multiparticulate systems through mucosal membranes. In a preferred embodiment, the present invention is a tablet for oral delivery of a drug, comprising a core including a drug to be delivered intestinally, and optionally a polymeric coating, which is not bioadhesive. In a preferred embodiment, the bioadhesive polymeric coating does not substantially swell upon hydration. The present invention is not limited to tablets, it may contain capsules, pellets, mini-tablets, granules, monolithic tablets spherules and the like, known to a person skilled in the art at the time of invention. Also these dosage forms can be prepared by any convention method known in the prior art. Another embodiment of the present invention wherein the expandable drug delivery system is in the form of mini-tables filled into the capsules. The dosage form of the present invention may contain carbon dioxide releasing agent which releases carbon dioxide, that forms a bubble layer around the dosage form which acts as a protective layer against enzymatic degradation. The bubble layer formed by gas generating component will remain intact in the dosage form until it reaches the intestinal wall and adheres to the intestinal mucosa. The gas generating component is also the transport medium bringing the drug compartment to the absorbing mucosal surface. As the dosage form enters into the intestine the enteric coating dissolves and the bubble layer formed due to the gas releasing agent that will prevent the hydration of
the mucoadhesive polymer which in turn prevents the dosage form to adhere to the mucin or mucosa till it reaches the specific site. The present invention provides methods for improving the bioadhesive properties of drug delivery systems such as tablets, capsules and drug-eluting devices. The invention also provides methods for improving the adhesion of drug delivery systems to mucosal membranes including membranes of the gastrointestinal tract. The polymeric drug delivery systems of the invention have an improved ability to bind to mucosal membranes, and thus can be used to deliver a wide range of drugs or diagnostic agents in a wide variety of therapeutic applications, and/or improve uptake of the active agent across the intestinal mucosa. In embodiments of the present invention, the pharmaceutical composition includes a mucoadhesive/ Bioadhesives. The mucoadhesive facilitates retention in the GIT by binding to the mucosal surface of the GIT, or by association with the mucosal coat. Examples of mucoadhesives include, but are not limited to, a polyacrylic acid or polyacrylate optionally cross-linked with allyl sucrose, allyl ethers of sucrose, allylpentaerythritol, pentaerythritol or divinyl glycol; a carboxylvinyl polymer; a polyvinyl pyrrolidone (PVP); polyvinyl alcohol; chitosan and its quaternary derivatives sodium carboxymethylcellulose (CMC); a dextran polymer; a copolymer of polymethyl vinyl ether and maleic anhydride; hydroxymethylcellulose; methylcellulose; a tragacanth; an alginic acid; gelatin; gum arabic; and a polysaccharide optionally interrupted with a [beta]-(l-4)-linked D-glucosamine unit and/or a N-acetyl-D-glucosamine unit, and mixtures thereof. The preferred embodiment of the present invention involves the preparation of expandable delivery system in which the dosage form after administration reaches the desired site of action and will forms a temporary adhesion to the mucous surface followed by imbibing the fluids of the Gl environment in to the core, where it discloses the force generating material in the core which creates a force to expand
the dosage form and carries it for adhesion to luminal surface with out loosing its mucoadhesive properties. The drug present in polymer matrix diffuses through the intestinal wall by diffusion. The delivery system, which got adherered to the walls of the intestine, slides down as the mucous membrane sheds down and reaches the large intestine where the dosage from is degraded or expelled as such. The preferred embodiment of the present invention may include other excipient like absorption enhancers enzyme inhibitors and intestinal motility modifiers can be integrated in the polymer matrix. In order to increase epithelial permeability, all compounds that are used as permeation enhancers can be integrated in the swellable polymer matrix. Examples of such compounds are EDTA, polyacrylates (Carbomer), chitosans and their derivatives, anionic surfactants such as sodium lauryl sulfate, nonionic surfactants such as polyoxyethylene ethers and esters, fatty acids such as sodium caprate, trihydroxy bile salts such as taurocholate, dihydroxy bile salts such as taurodeoxycholate, acyl carnitines such as palmitoyl carnitine and salicylates such as sodium salicylate, carbon dioxide and the like. In order to reduce enzymatic activity all known classes of protease inhibitors and other enzyme inhibiting substances can be added in the swellable polymer matrix. Enzyme inhibitors improve the absorption of macromolecular drugs. Compounds, which increase epithelial permeability and reduce enzymatic activity simultaneously, can also be added. Suitable enzyme inhibitors are aprotinin, cystatin, amino acid and its derivates, soybean trypsin inhibitor, leupeptin, bestatin and small inhibitors based on boron compounds, such ASA- aminoboronic acid derivatives. Another application possibility is the use of ketoconazol and levamisol as enzyme inhibitors for cytochromes such as cytochrome P450 and especially for cytochrome P3A4 and for other drug transporters such as P-glycoproteins within the gut wall to overcome multidrug resistance of drugs especially anti-cancer drugs.
Further optional ingredients are compounds that can control the intestinal motility, either decrease the motility for prolonged retention time of the dosage form at the site of action or increase the motility for easier excretion of the dosage form. These compounds can influence the transition of the system through specific parts of the intestine. Examples of such compounds are loperamide.HCI, papaverine.HCI, opiate receptor stimulators and acetylcholine antagonists. Other Excipients The pharmaceutical composition may also contain other conventional pharmaceutical excipients, for example, water soluble diluents such as lactose, dextrose, mannitol, sorbitol, and the like; water insoluble diluents such as starch, microcrystalline cellulose, powdered cellulose, and the like; or lubricants such as talc, stearic acid or its salt, magnesium stearate, and the like. According to the present invention, when the pharmaceutical composition contains a water-soluble salt of one or more polyuronic acids, the other pharmaceutical excipients preferably should be free of calcium ions. The invention is not limited to the examples given in the specification it may include other excipients, which are known in the field of invention. The delivery system was prepared by any know granulation technique with the citric acid, Na-bicarbonate and lactose. TMC (Trimethyle chitosan), PEO, Avicel, drug and the Na-benzoate were then added step-wise to the obtained granules and mixed. The granules were then pressed to tablets. The variables were the percent polyethylene oxide (PEO) as mucoadhesive polymer, percent of citric acid and Na-bicarbonate (CO gas production), and Ac-Di-Sol as super-disintegrant. The response was the CO gas production, tablet disintegration as well as a mucoadhesive mass response. The variables were set as low and high values of 2.5 - 70% of the total weight for the amount of acid-base, Ac-Di-Sol and the PEO, respectively. The prepared tables were coated with an enteric coating polymer(s).
In one of the present embodiment the use of the Co2 and the TMC had shown a synergist effect on the permeability of the insulin across ex-vivo isolated sheep's intestine. The apparent permeability for insulin using the expandable drug delivery system in the presence of TMC has shown a highest value of 27 *10'7 (cm/sec) as shown in Fig 1 which describes the effect of the GEDD system on the transport of the insulin across the sheep's intestine.
Examples: This example illustrates the present invention when the active ingredient is peptide drug. Peptide drug is an example of a drug, which is absorbed, only from the upper part of the intestine. The pharmaceutical composition is given in Table 1.
DETERMINATION OF MUCOADHESION The mucoadhesive properties of the system were evaluated in a piece of sheep's intestine (Jejunum). The experiment was performed according to the method described by Smart et al. with some modifications. Briefly, a small section of fresh
sheep's intestine was removed, quickly frozen and was cut into pieces of 3 cm lengths, opened longitudinally to expose the mucous surface and gently washed with PBS buffer pH 6.0. A preliminary histological study indicated the absence of any major damage to the tissue caused by the freeze-thawing process. A layer of mucus was shown to be present on the inner surface of the intestine. The sections of intestine were mounted on a platform and secured using a plastic cap, exposing an 11 mm diameter of the test surface. The exposed surface was equilibrated in PBS o buffer of pH 6.8 for 1 min at 37 C. The cap was elongated at one side to allow sufficient distance for the tablet to be detached. Using a cyanoacrylate adhesive, the GEDD tablets were individually attached to 1.5 g weight, lowered into PBS buffer pH 6.8 and placed in contact with the adhesive surface for 2 minutes. Subsequently, a brass ring was placed over the 1.5 g weight. The ring was connected to the force and position sensor of the rheometer via a pulley system (diagram 1). After 2 min the contact platform was lowered at a rate of 2mm/min and the maximum detachment force was calculated.
We claim: 1. An expandable drug delivery system comprising of one or more actives, force generating components, optionally containing one or more absorption modifiers 2. An expandable drug delivery system of claim 1 where in the force generating component is selected from the group consisting of gas generating components, swelling polymers and osmogens 3. An expandable drug delivery system of claim 1 where in the swelling polymers polymer is selected from the group consisting of cellulose and its derivatives, PEO, gums, PVP, cross linked PVP, sodium starch glycolate, cross linked cellulose, polysaccharides, cross linked polyacrylic acids, polyalkyl oxides, polyurethane hydrogels, malic anhydrate polymers and chitosan 4. An expandable drug delivery system for oral delivery consisting of macromolecular active, force generating component, with/with out absorption modifiers 5. An expandable drug delivery system of claim 3 where in the macromolecular actives selected from the group consisting of proteins; polypeptides; peptides; hormones; polysaccharides, and particularly mixtures of muco-polysaccharides; carbohydrates; lipids; small polar organic molecules 6. An expandable drug delivery system for oral delivery consisting of a protein or peptide drug(s), force-generating components, with/with out absorption modifiers, wherein the composition is formulated to increase the residence time in the GIT, optionally coated with enteric polymers.
7. An expandable drug delivery system for oral delivery in the form of multilayered tablets or capsules comprising protein or peptide, PEO, TMC, force-generating component and optionally coated. 8. An expandable drug delivery system of claim 6 wherein the multilayered tablet or capsules comprise of one or more layer. 9. An expandable drug delivery system according to any preceding claims the increase in the gastric retention is achieved by the use of mucoadhesion or bioadhesion 10. An expandable drug delivery system according to claim 8 the coating polymer is a hydrophilic or hydrophobic polymers. 11.An expandable drug delivery system consisting of a peptide drug, expandable polymer matrix, expanding force-generating component, which delivers drug after a lag time followed by a burst release or sustained release.
An expandable drug delivery system comprising of one or more actives, force generating components, optionally containing one or more absorption modifiers